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Background
For various reasons it can be necessary to administer
antiretrovirals permanently or temporarily in a dissolved
form: swallowing difficulties, stomach tube or patients
in an ICU. However, not all drugs are available as oral
solution. Crushing and dissolving may be an option, but
data on plasma levels and efficacy are limited or not
existing.
Methods
We report efficacy and plasma level data for two
patients, one with dysphagia and Candida esophagitis
and one with a stomach tube, who received darunavir
(DRV) crushed and dissolved.
Results
Patient 1 is 57 year old HIV+ male (CDC C3), first diag-
nosed in 1990, who has been on various antiretroviral
regimens since 1992. He presented with a VL of 72.551
copies/mL, 56 CD4 cells/mm
3 and candida esophagitis.
HAART was initiated with DRV/RTV 600/100 mg in
combination with etravirine (ETR) and raltegravir
(RAL). DRV and RAL tablets were crushed, ETR was
suspended and ritonavir (RTV) was given as oral solu-
tion. The medication was well accepted with exception
of RTV oral solution. Trough levels (10 h post dose) for
DRV were 6.950 ng/mL; measured one month post
treatment initiation. At that time, VL had declined to
102 copies/mL; CD4 count had increased to 111 cells/
mm
3. The patient was then switched to tablets, viral
load has been <40 copies/mL since then.
Patient 2 is a 48 year old HIV+ paraplegic woman
(CDC C3), first diagnosed in 2004 with a permanent
stomach tube. HAART with DRV/RTV 600/100 mg bid,
RAL and tenofovir/emtricitabine via tube was initiated
in 2008. Since then, viral load has been permanently <
40 copies/mL; CD4 count is stable between 440 and 540
cells/mm
3. Plasma levels for DRV were within the thera-
peutic range: 4.430 ng/mL (5 hours post dose) in Janu-
ary and 5.210 ng/mL (3 hours post dose) in June.
Conclusions
Crushing DRV tablets and combining them with RTV
oral solution reached adequate DRV plasma levels. In
these two patients, HAART administered via artificial
feeding was an effective option for short and long-term
treatment.
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